| Products/Services Used | Details | Operation |
|---|---|---|
| Recombinant Proteins> | GenBank accession EF541402), HIV-1 1086 C Env, SOSIP stabilized HIV-1 1086 C Env, or NFL-TD stabilized HIV-1 1086 C Env respectively (Genscript, Piscataway, NJ, USA). | Get A Quote |
HIV-1 Env glycoprotein (Env) immunogenicity is limited in part by structural instability and extensive glycan shielding and is likely the greatest obstacle to an HIV-1 vaccine. Stabilized Env trimers can elicit serum neutralizing antibodies, but the response is short-lived. Here we use Newcastle Disease Virus-like particle (NDV-VLP) platform to present stabilized versions of HIV-1 Env at high valency and in the context of varied conformational stability, adjuvants, dose, and antigen persistence. Influenza virus hemagglutinin, or SARS-CoV2 Spike-bearing VLPs rapidly induce neutralizing antibodies, in contrast, they were not induced by those bearing Env. A replicating adenovirus type 4 expressing Env rapidly indu... More